Welcome to our dedicated page for Oric Pharmaceuticals SEC filings (Ticker: ORIC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. ORIC is a clinical stage oncology company with common stock registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Global Select Market under the symbol ORIC, as reflected in its Form 8-K filings.
Investors can review current reports on Form 8-K in which ORIC discloses material events such as quarterly financial results, clinical program updates, and corporate presentations. For example, the company has filed 8-Ks to announce financial results for quarters ended June 30 and September 30, 2025, to furnish updated ORIC-944 corporate presentation slides, and to provide an enozertinib (ORIC-114) program update summarizing Phase 1b trial data. Certain 8-Ks also describe strategic pipeline prioritization measures, including workforce reductions and a focus on lead programs ORIC-944 and enozertinib.
ORIC’s filings include details on its status as an emerging growth company, the registration of its common stock on The Nasdaq Global Select Market, and exhibits such as press releases and investor presentations. These documents also contain cautionary notes regarding forward-looking statements and refer readers to risk factor discussions in periodic reports like Form 10-Q.
On Stock Titan, ORIC’s filings are updated in near real time from the SEC’s EDGAR system. AI-powered summaries help explain the key points of lengthy filings by highlighting items such as reported financial results, clinical milestones, strategic changes, and capital raising activities. Users can quickly see what each 8-K covers, identify attached exhibits such as presentations, and understand how new disclosures may relate to ORIC’s oncology pipeline and Nasdaq-listed equity.
In addition to 8-Ks, this page links to ORIC’s other SEC documents available on EDGAR, allowing investors to follow the company’s regulatory history, governance disclosures, and risk factor updates as its clinical programs advance.
A holder of ORIC common stock has filed a notice to sell 6,400 shares under Rule 144. The planned sale is through J.P. Morgan Securities LLC on the Nasdaq, with an indicated aggregate market value of $76,800 and the class having 97,389,279 shares outstanding.
The shares to be sold were originally acquired on 07/31/2015 through a stock option exercise from the issuer, paid in cash on the same date. The filer represents that they do not know of any material adverse, nonpublic information about ORIC’s current or future operations.
ORIC Pharmaceuticals filed a notice that a shareholder plans to sell 7,000 shares of common stock through J.P. Morgan Securities LLC on Nasdaq, with an aggregate market value of $84,000. The filing lists 97,389,279 shares of common stock outstanding. The shares to be sold were acquired on 08/25/2016 by exercising stock options for cash on that same date.
Oric Pharmaceuticals director files insider transaction report for new stock options. Director Lori Anne Kunkel reported receiving a stock option covering 40,000 shares of Oric Pharmaceuticals common stock on January 2, 2026. The option has an exercise price of $8.17 per share and is held as a derivative security with direct ownership. According to the vesting terms, 1/12 of the shares subject to the option vest on each monthly anniversary of January 2, 2026, resulting in full vesting over one year. The option is scheduled to expire on January 1, 2036, if not exercised earlier.
Oric Pharmaceuticals director Steven L. Hoerter reported a new stock option grant for 40,000 shares of common stock. The option, with an exercise price of $8.17 per share, was awarded on January 2, 2026 and is held directly. It is scheduled to vest in equal monthly installments, with 1/12 of the shares vesting on each one-month anniversary of January 2, 2026, until fully vested. The option expires on January 1, 2036, giving the director a long-dated right to purchase Oric common shares at the fixed exercise price.
Oric Pharmaceuticals, Inc. director Richard A. Heyman reported receiving a stock option grant for 40,000 shares of common stock. The option has an exercise price of $8.17 per share and expires on January 1, 2036. According to the vesting schedule, 1/12 of the shares under the option vest on each monthly anniversary of January 2, 2026, resulting in full vesting over one year. Following this grant, he beneficially owns 40,000 stock options directly.
Oric Pharmaceuticals Chief Financial Officer Dominic Piscitelli reported new equity awards. On January 2, 2026, he received a stock option covering 206,500 shares of Oric common stock with an exercise price of $8.17 per share. According to the vesting terms, 25% of these option shares vest on January 2, 2027, and the remaining shares vest in equal monthly installments over the following 36 months.
He was also granted 34,500 restricted stock units (RSUs), each representing a right to receive one share of Oric common stock. One-third of these RSUs vests on each of December 15, 2026, December 15, 2027, and December 15, 2028. Both the option and RSUs are reported as directly owned and were acquired as part of his compensation.
Oric Pharmaceuticals Chief Medical Officer Pratik S. Multani received new equity awards in the form of stock options and restricted stock units. On January 2, 2026, he was granted stock options covering 214,000 shares of Oric common stock at an exercise price of $8.17 per share. According to the vesting schedule, 25% of these options will vest on January 2, 2027, with the remaining options vesting in equal monthly installments over the following 36 months.
He was also granted 35,500 restricted stock units, each representing a contingent right to receive one share of Oric common stock. One-third of these RSUs will vest on each of December 15, 2026, December 15, 2027, and December 15, 2028, subject to the award terms. All reported holdings are listed as directly owned.
Oric Pharmaceuticals, Inc. insider equity activity shows its Chief Medical Officer reporting routine stock transactions. On December 15, 2025, the officer acquired 29,333 shares of Oric common stock at $0 through the vesting and settlement of restricted stock units (RSUs). The filing states that each RSU represents a right to receive one share of common stock.
On December 16, 2025, the officer sold 10,720 shares of common stock at a weighted average price of $9.0605 per share to cover tax withholding obligations tied to the RSU vesting, described as not a discretionary sale. After these transactions, the officer beneficially owned 68,149 shares of Oric common stock, including 2,771 shares acquired under the company’s 2020 Employee Stock Purchase Plan.
Oric Pharmaceuticals, Inc. reported insider equity activity by its Chief Financial Officer. On 12/15/2025, the CFO acquired 29,333 shares of common stock at an exercise price of
On 12/16/2025, the CFO sold 10,720 shares of common stock at a weighted average price of
Oric Pharmaceuticals, Inc. reported an equity transaction by its President and CEO, who is also a director. On December 15, 2025, the executive acquired 83,666 shares of common stock at $0 upon the vesting and settlement of restricted stock units (RSUs). On December 16, 2025, 33,374 shares of common stock were sold at a weighted average price of $9.06 to cover tax withholding obligations related to the RSU vesting, described as a non-discretionary sale. Following these transactions, the executive beneficially owned 581,711 shares of Oric common stock directly, with additional RSUs remaining subject to vesting over future dates.
FAQ
What is the current stock price of Oric Pharmaceuticals (ORIC)?
What is the market cap of Oric Pharmaceuticals (ORIC)?
